MapLight Therapeutics, Inc. (NASDAQ:MPLT) recently saw significant insider activity as Jonathan Gillis, the company's Chief Accounting Officer and Principal Accounting Officer, divested a substantial portion of his holdings. The transactions took place on April 27 and April 28, 2026, resulting in total sales of $2,087,687.
The execution of these trades occurred as the stock was trading near its current level of $30.29, with the sale prices ranging from a weighted average of $28.94 to $30.83 per share. This divestment follows an intensive six-month period where MapLight Therapeutics saw an 83% surge in share value, bringing the stock close to its 52-week high of $33.28.
Detailed Transaction Breakdown
The sales on April 27 involved three distinct transaction blocks totaling 51,900 shares:
- A sale of 7,914 shares at a weighted average price of $28.94 (with individual prices between $28.27 and $29.25).
- A sale of 29,623 shares at a weighted average price of $29.60 (with individual prices between $29.27 and $30.25).
- A sale of 14,363 shares at a weighted average price of $30.46 (with individual prices between $30.27 and $30.64).
On the following day, April 28, Mr. Gillis completed two additional transactions totaling 17,935 shares:
- 17,235 shares sold at a weighted average price of $30.33 (with individual prices between $29.755 and $30.71).
- 700 shares sold at a weighted average price of $30.83 (with individual prices between $30.81 and $30.86).
Following the conclusion of these sales, Jonathan Gillis retains a direct holding of 181,219 shares of MapLight Therapeutics common stock.
Market Context and Analyst Perspectives
While the insider selling has drawn attention, broader market sentiment remains focused on the company's clinical pipeline. TD Cowen recently initiated coverage with a buy rating, focusing on MapLight's therapeutic developments for neuropsychiatric and central nervous system conditions. A key point of interest is the lead asset, ML-007C-MA, which is designed to target schizophrenia treatment.
Stifel has also maintained its optimism, reiterating a buy rating and a price target of $28.00 following the company's fourth-quarter update. Analysts have noted that the M1/M4 mechanism for ML-007C-MA is considered de-risked by the presence of Cobfeny. The industry is currently awaiting Phase 2 data for ML-007C-MA, which is anticipated in the third quarter of 2026. Analysts suggest that MapLight could potentially differentiate itself through improvements in dosing frequency, safety profiles, or tolerability.